Neha Narula, MD
Family Practice · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Narula’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A147536 · Current
Licensed to practise in California · since 2017 · expires 2027-01-31 · Wayne State University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$11,062
Medicare paid this office $11,062 for 68 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 36 | $4,966 | $66 |
| Short return visit (20+ min) | 33 | $3,151 | $53 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 19 | $933 | $49 |
| Short return visit | 12 | $611 | $51 |
Who their Medicare patients are
68 Original Medicare patients in 2024. Average age 70 · Women 62% · Also on Medicaid 37% · Health risk score 1.72. Above the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 69% · Diabetes 47% · Depression 38% · Chronic kidney disease 24% · Coronary heart disease 18%.
The office billed $122,908, Medicare allowed $16,724 and paid $11,062; for 183 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 68 | 183 | 70 | 1.72 | $122,908 | $11,062 |
| 2023 | 82 | 154 | 72 | 1.92 | $95,011 | $8,572 |
| 2022 | 43 | 66 | 71 | 1.58 | $39,145 | $4,078 |
| 2021 | 86 | 160 | 69 | 1.71 | $65,351 | $8,046 |
| 2020 | 122 | 269 | 71 | 1.72 | $71,122 | $14,036 |
| 2019 | 138 | 258 | 71 | 1.61 | $38,194 | $15,952 |
| 2018 | 43 | 55 | 70 | 1.48 | $7,114 | $3,718 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 39 | $3,059 | $52 |
| Short return visit (20+ min) | 41 | $2,593 | $52 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $1,312 | $82 |
2022: 2 services
| Return visit (30+ min) | 27 | $1,966 | $63 |
| Short return visit (20+ min) | 12 | $715 | $55 |
2021: 5 services
| Short return visit (20+ min) | 36 | $2,623 | $49 |
| Return visit (30+ min) | 23 | $2,073 | $59 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | $997 | $83 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $807 | $47 |
| Short return visit | 14 | $505 | $36 |
2020: 5 services
| Short return visit (20+ min) | 67 | $4,384 | $39 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 17 | $2,404 | $141 |
| Return visit (30+ min) | 20 | $1,958 | $65 |
| Telephone medical discussion with physician, 11-20 minutes | 28 | $1,787 | $47 |
| Telephone medical discussion with physician, 5-10 minutes | 19 | $570 | $23 |
2019: 4 services
| Short return visit (20+ min) | 95 | $5,971 | $41 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 25 | $3,477 | $139 |
| Return visit (30+ min) | 43 | $3,288 | $66 |
| New patient visit (45+ min) | 17 | $1,769 | $104 |
2018: 2 services
| Short return visit (20+ min) | 23 | $1,152 | $46 |
| Return visit (30+ min) | 14 | $989 | $71 |
Drugs they prescribed that Part D paid
$192,000
Pharmacies billed $192,000 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (17 of 926) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
787 generic and fewer than 11 brand-name prescriptions · $192,000 in drug cost · 18 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Otezla | 12 | $58,907 | $4,909 |
| Mounjaro | 18 | $23,652 | $1,314 |
| Jardiance | 12 | $17,667 | $1,472 |
| Trulicity | 13 | $11,723 | $902 |
| Duloxetine | 31 | $799 | $26 |
See all 26 drugs
| Otezla | 12 | $58,907 | $4,909 |
| Mounjaro | 18 | $23,652 | $1,314 |
| Jardiance | 12 | $17,667 | $1,472 |
| Trulicity | 13 | $11,723 | $902 |
| Duloxetine | 31 | $799 | $26 |
| Gabapentin | 22 | $786 | $36 |
| Mirtazapine | 11 | $784 | $71 |
| Albuterol Sulfate Hfa | 12 | $756 | $63 |
| Ondansetron Odt | 11 | $615 | $56 |
| Atorvastatin | 53 | $547 | $10 |
| Amlodipine Besylate | 42 | $429 | $10 |
| Hydrocodone-Acetaminophen | 11 | $309 | $28 |
| Rosuvastatin | 24 | $291 | $12 |
| Fluticasone Propionate | 20 | $231 | $12 |
| Rizatriptan | 14 | $223 | $16 |
| Celecoxib | 17 | $209 | $12 |
| Sumatriptan | 11 | $182 | $17 |
| Sertraline | 12 | $148 | $12 |
| Metformin | 29 | $143 | $5 |
| Famotidine | 12 | $134 | $11 |
| Cyclobenzaprine | 12 | $116 | $10 |
| Lisinopril | 19 | $85 | $4 |
| Carvedilol | 15 | $82 | $5 |
| Losartan | 16 | $75 | $5 |
| Hydrochlorothiazide | 13 | $74 | $6 |
| Alendronate | 12 | $62 | $5 |
Year by year
| 2024 | 926 | 186 | 2% (17) | None | $192,000 |
| 2023 | 812 | 154 | 3% (21) | None | $204,122 |
| 2022 | 486 | 102 | 4% (18) | None | $70,659 |
| 2021 | 1,042 | 137 | 2% (22) | None | $116,319 |
| 2020 | 1,502 | 184 | 4% (62) | None | $162,445 |
| 2019 | 1,096 | 147 | 7% (78) | None | $100,795 |
| 2018 | 454 | 95 | 4% (18) | 14% | $32,508 |
| 2017 | 352 | 63 | 7% (25) | 10% | $20,964 |
| 2016 | 120 | 34 | 0% (0) | 23% | $62,604 |
| 2015 | 192 | 43 | None | 32% | $145,768 |
| 2014 | 40 | 15 | None | 0% | $1,221 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Jardiance | 16 | $18,941 | $1,184 |
| Trulicity | 14 | $15,983 | $1,142 |
| Duloxetine | 36 | $699 | $19 |
| Rosuvastatin | 13 | $646 | $50 |
| Atorvastatin | 49 | $636 | $13 |
| Tamsulosin | 12 | $356 | $30 |
| Fluticasone Propionate | 16 | $319 | $20 |
| Amlodipine Besylate | 26 | $311 | $12 |
| Hydrocodone-Acetaminophen | 14 | $258 | $18 |
| Lisinopril | 21 | $207 | $10 |
| Omeprazole | 11 | $184 | $17 |
| Gabapentin | 16 | $165 | $10 |
| Levothyroxine | 11 | $164 | $15 |
| Sumatriptan | 15 | $162 | $11 |
| Losartan | 15 | $113 | $8 |
| Carvedilol | 11 | $112 | $10 |
| Metformin | 14 | $112 | $8 |
| Hydrochlorothiazide | 13 | $63 | $5 |
2022: 8 drugs
| Sumatriptan | 13 | $394 | $30 |
| Levothyroxine | 15 | $285 | $19 |
| Losartan | 22 | $254 | $12 |
| Amlodipine Besylate | 22 | $223 | $10 |
| Atorvastatin | 26 | $221 | $8 |
| Hydrocodone-Acetaminophen | 16 | $195 | $12 |
| Clopidogrel | 11 | $92 | $8 |
| Lisinopril | 11 | $69 | $6 |
2021: 31 drugs
| Ozempic | 21 | $19,616 | $934 |
| Trulicity | 12 | $15,800 | $1,317 |
| Jardiance | 15 | $10,585 | $706 |
| Lantus Solostar | 12 | $4,458 | $371 |
| Atorvastatin | 46 | $1,320 | $29 |
| Levothyroxine | 30 | $728 | $24 |
| Losartan | 34 | $694 | $20 |
| Albuterol Sulfate Hfa | 13 | $652 | $50 |
| Amlodipine Besylate | 51 | $649 | $13 |
| Duloxetine | 16 | $626 | $39 |
| Sumatriptan | 18 | $510 | $28 |
| Gabapentin | 13 | $337 | $26 |
| Diclofenac | 16 | $331 | $21 |
| Allopurinol | 23 | $325 | $14 |
| Alendronate | 20 | $287 | $14 |
| Tamsulosin | 19 | $264 | $14 |
| Hydrocodone-Acetaminophen | 22 | $249 | $11 |
| Fluticasone Propionate | 26 | $243 | $9 |
| Pravastatin | 13 | $229 | $18 |
| Lisinopril | 17 | $226 | $13 |
| Clopidogrel | 16 | $169 | $11 |
| Topiramate | 11 | $167 | $15 |
| Ondansetron Odt | 13 | $160 | $12 |
| Metformin | 23 | $154 | $7 |
| Benazepril | 15 | $148 | $10 |
| Famotidine | 14 | $131 | $9 |
| Atenolol | 14 | $128 | $9 |
| Hydrochlorothiazide | 17 | $103 | $6 |
| Simvastatin | 22 | $102 | $5 |
| Glimepiride | 13 | $80 | $6 |
| Metoprolol | 13 | $68 | $5 |
2020: 40 drugs
| Novolog Flexpen | 12 | $22,175 | $1,848 |
| Ozempic | 13 | $10,394 | $800 |
| Lantus Solostar | 13 | $4,622 | $356 |
| Gabapentin | 42 | $1,772 | $42 |
| Duloxetine | 35 | $1,294 | $37 |
| Atorvastatin | 66 | $1,103 | $17 |
| Mirtazapine | 20 | $768 | $38 |
| Losartan | 41 | $742 | $18 |
| Sumatriptan | 20 | $660 | $33 |
| Levothyroxine | 22 | $582 | $26 |
| Allopurinol | 42 | $582 | $14 |
| Diclofenac | 23 | $549 | $24 |
| Amlodipine Besylate | 61 | $536 | $9 |
| Lisinopril | 34 | $483 | $14 |
| Hydrocodone-Acetaminophen | 42 | $471 | $11 |
| Escitalopram | 22 | $443 | $20 |
| Metformin Hcl Er | 17 | $428 | $25 |
| Pravastatin | 13 | $403 | $31 |
| Fluticasone Propionate | 28 | $402 | $14 |
| Rosuvastatin | 11 | $391 | $36 |
| Ondansetron Odt | 21 | $382 | $18 |
| Tamsulosin | 20 | $375 | $19 |
| Alendronate | 21 | $308 | $15 |
| Topiramate | 21 | $304 | $14 |
| Terazosin | 11 | $292 | $27 |
| Oxybutynin Chloride | 11 | $288 | $26 |
| Losartan-Hydrochlorothiazide | 13 | $266 | $20 |
| Metoprolol | 16 | $250 | $16 |
| Pantoprazole | 19 | $229 | $12 |
| Clopidogrel | 17 | $210 | $12 |
| Metformin | 20 | $191 | $10 |
| Diazepam | 24 | $187 | $8 |
| Cyclobenzaprine | 22 | $181 | $8 |
| Simvastatin | 40 | $158 | $4 |
| Famotidine | 11 | $146 | $13 |
| Lisinopril-Hydrochlorothiazide | 14 | $132 | $9 |
| Atenolol | 14 | $131 | $9 |
| Hydrochlorothiazide | 22 | $110 | $5 |
| Furosemide | 13 | $78 | $6 |
| Metoprolol | 13 | $47 | $4 |
2019: 33 drugs
| Trulicity | 17 | $20,674 | $1,216 |
| Eliquis | 12 | $7,101 | $592 |
| Buprenorphine | 16 | $5,109 | $319 |
| Gabapentin | 27 | $1,510 | $56 |
| Duloxetine | 19 | $1,237 | $65 |
| Atorvastatin | 42 | $734 | $17 |
| Sumatriptan | 19 | $635 | $33 |
| Levothyroxine | 23 | $502 | $22 |
| Hydrocodone-Acetaminophen | 51 | $473 | $9 |
| Losartan | 37 | $468 | $13 |
| Lisinopril | 31 | $328 | $11 |
| Escitalopram | 29 | $326 | $11 |
| Allopurinol | 18 | $323 | $18 |
| Pravastatin | 13 | $322 | $25 |
| Mirtazapine | 12 | $315 | $26 |
| Amlodipine Besylate | 28 | $288 | $10 |
| Tamsulosin | 15 | $259 | $17 |
| Isosorbide Mononitrate Er | 13 | $171 | $13 |
| Fluticasone Propionate | 17 | $170 | $10 |
| Pantoprazole | 12 | $169 | $14 |
| Atenolol | 14 | $164 | $12 |
| Triamterene-Hydrochlorothiazid | 11 | $161 | $15 |
| Topiramate | 11 | $137 | $12 |
| Lisinopril-Hydrochlorothiazide | 13 | $136 | $10 |
| Metformin | 16 | $125 | $8 |
| Glipizide | 12 | $117 | $10 |
| Alprazolam | 15 | $102 | $7 |
| Metoprolol | 15 | $81 | $5 |
| Furosemide | 11 | $78 | $7 |
| Sertraline | 11 | $71 | $6 |
| Prednisone | 11 | $69 | $6 |
| Simvastatin | 11 | $48 | $4 |
| Hydrochlorothiazide | 11 | $37 | $3 |
2018: 9 drugs
| Hydrocodone-Acetaminophen | 16 | $285 | $18 |
| Levothyroxine | 13 | $212 | $16 |
| Atorvastatin | 15 | $177 | $12 |
| Omeprazole | 17 | $176 | $10 |
| Sertraline | 12 | $125 | $10 |
| Simvastatin | 13 | $120 | $9 |
| Amlodipine Besylate | 15 | $80 | $5 |
| Lisinopril | 12 | $67 | $6 |
| Prednisone | 11 | $27 | $2 |
2017: 11 drugs
| Levothyroxine | 17 | $198 | $12 |
| Hydrocodone-Acetaminophen | 14 | $187 | $13 |
| Atorvastatin | 14 | $166 | $12 |
| Amlodipine Besylate | 19 | $157 | $8 |
| Trazodone | 15 | $135 | $9 |
| Gabapentin | 12 | $112 | $9 |
| Omeprazole | 12 | $101 | $8 |
| Lisinopril | 24 | $87 | $4 |
| Pantoprazole | 17 | $81 | $5 |
| Metformin | 11 | $80 | $7 |
| Sertraline | 14 | $62 | $4 |
2016: 2 drugs
| Mycophenolate Mofetil | 12 | $1,115 | $93 |
| Prednisone | 45 | $669 | $15 |
2015: 3 drugs
| Humira | 21 | $84,105 | $4,005 |
| Methotrexate | 19 | $2,655 | $140 |
| Prednisone | 80 | $1,470 | $18 |
2014: 1 drug
| Prednisone | 26 | $518 | $20 |
Professional record
- NPI
- 1336586130
- Licence
- CA A147536California A147536: Current · expires 2027-01-31
- Trained
- Wayne State University School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94305
- NPI first listed
- 2013-06-03
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.